Klishadi Mohsen Sharifi, Zarei Farideh, Hejazian Seyyed Hassan, Moradi Ali, Hemati Mahdieh, Safari Fatemeh
Department of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
J Pharm Pharm Sci. 2015;18(1):112-23. doi: 10.18433/j3xg7t.
Sirtuin-3 (SIRT3) deacetylase protects the heart against oxidative stress via survival factors upregulation. Clinical and experimental studies have demonstrated that activation of systemic and local renin-angiotensin system (RAS) is implicated in ischemia-induced cardiac injury. However, the relation between RAS and SIRT3 in pathophysiology of myocardial ischemia reperfusion is unknown. In this study, the cardiac transcription and expression of SIRT3 levels was examined in response to ischemia reperfusion in untreated and losartan treated rats.
Rats were divided into control group, losartan group (L), and ischemia reperfusion (IR) groups with (L+IR) or without losatran pretreatment. Some rats were included as sham-operated and saline groups. IR was induced by left anterior descending artery occlusion. SIRT3 protein levels were determined by Western blot technique. The genes expression was specified by real-time RT-PCR. Arrhythmias were assessed according to the Lambeth conventions.
In L+IR group a significant reduction was noted in the number of ventricular ectopic beats (VEBs) and episodes of ventricular tachycardia (VT) (VEBs: P<0.001; VT: P<0.01 vs. IR). In IR group, SIRT3 protein level was decreased in the ischemic tissue by 26.7±5.9% (P<0.01 vs. Control). However, in the non-ischemic tissue the changes of SIRT3 protein content were not significant. In L+IR group SIRT3 protein levels in the ischemic part of Left ventricle were significantly different from IR group (P<0.001). SIRT3 mRNA level did not change significantly among the experimental groups. Thioredoxin-1 and catalase transcription level was increased in L+IR group compared to IR group (P<0.01).
A decreased SIRT3 protein levels subsequent to IR might be a novel signaling mechanism involved in IR injury. Losartan at non-hypotensive dose exerts anti-ischemic effects in part by normalizing the SIRT3 protein level and upregulating the survival factors encoding genes transcription in ischemic tissue of the heart.
沉默调节蛋白3(SIRT3)脱乙酰酶通过上调生存因子来保护心脏免受氧化应激。临床和实验研究表明,全身和局部肾素-血管紧张素系统(RAS)的激活与缺血性心脏损伤有关。然而,RAS与SIRT3在心肌缺血再灌注病理生理学中的关系尚不清楚。在本研究中,检测了未治疗和氯沙坦治疗的大鼠在缺血再灌注后心脏中SIRT3水平的转录和表达情况。
将大鼠分为对照组、氯沙坦组(L)以及有(L+IR)或无氯沙坦预处理的缺血再灌注(IR)组。部分大鼠作为假手术组和生理盐水组。通过左前降支动脉闭塞诱导缺血再灌注。采用蛋白质印迹技术测定SIRT3蛋白水平。通过实时逆转录-聚合酶链反应确定基因表达。根据兰贝斯标准评估心律失常情况。
在L+IR组中,室性早搏(VEB)数量和室性心动过速(VT)发作次数显著减少(VEB:P<0.001;VT:与IR组相比,P<0.01)。在IR组中,缺血组织中SIRT3蛋白水平降低了26.7±5.9%(与对照组相比,P<0.01)。然而,在非缺血组织中,SIRT3蛋白含量变化不显著。在L+IR组中,左心室缺血部分的SIRT3蛋白水平与IR组有显著差异(P<0.001)。SIRT3 mRNA水平在各实验组之间无显著变化。与IR组相比,L+IR组中硫氧还蛋白-1和过氧化氢酶转录水平升高(P<0.01)。
缺血再灌注后SIRT3蛋白水平降低可能是缺血再灌注损伤中一种新的信号机制。非降压剂量的氯沙坦部分通过使SIRT3蛋白水平正常化并上调心脏缺血组织中生存因子编码基因的转录发挥抗缺血作用。